Abstract:Crohn's disease (CD) is a chronic relapsing disorder of the gastrointestinal tract and represents one of the main entities of inflammatory bowel disease (IBD). CD affects genetically susceptible patients that are influenced by environmental factors and the intestinal microbiome, which results in excessive activation of the mucosal immune system and aberrant cytokine responses. Various studies have implicated the pro-inflammatory cytokines IL17 and IL23 in the pathogenesis of CD. IL23 is a member of the IL12 family of cytokines and is able to enhance and affect the expansion of pathogenic T helper type 17 (Th17) cells through various mechanisms, including maintenance of Th17 signature genes, upregulation of effector genes or suppression of repressive factors. Moreover, IL17 and IL23 signaling is able to induce a cascade of pro-inflammatory molecules like TNF, IFNγ, IL22, lymphotoxin, IL1β and lipopolysaccharide (LPS). Here, IL17A and TNF are known to mediate signaling synergistically to drive expression of inflammatory genes. Recent advances in understanding the immunopathogenetic mechanisms underlying CD have led to the development of new biological therapies that selectively intervene and inhibit inflammatory processes caused by pro-inflammatory mediators like IL17 and IL23. Recently published data demonstrate that treatment with selective IL23 inhibitors lead to markedly high response rates in the cohort of CD patients that failed previous anti-TNF therapy. Macrophages are considered as a main source of IL23 in the intestine and are supposed to play a key role in the molecular crosstalk with T cell subsets and innate lymphoid cells in the gut. The following review focuses on mechanisms, pathways and specific therapies in Crohn's disease underlying the IL23/IL17 pathway.

Synergy of IL-23 and Th17 Cytokines: New Light on Inflammatory Bowel Disease

Potential Role of Th17 Cells in the Pathogenesis of Inflammatory Bowel Disease.

Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease.

Interplay of Intestinal Microbiota and Mucosal Immunity in Inflammatory Bowel Disease: a Relationship of Frenemies

The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases

Interleukin-23, its Receptor and Inflammatory Bowel Disease

The Increased Expression of IL-23 in Inflammatory Bowel Disease Promotes Intraepithelial and Lamina Propria Lymphocyte Inflammatory Responses and Cytotoxicity.

IL-33 and IL-18 in Inflammatory Bowel Disease Etiology and Microbial Interactions

Increased Expression of Interleukin-23 Induces Proinflammatory Cytokine Secretion in Inflammatory Bowel Disease

Dual Immune Functions of IL-33 in Inflammatory Bowel Disease.

The role of IL-19, IL-24, IL-21 and IL-33 in intestinal mucosa of inflammatory bowel disease: A narrative review

Interleukin (Il)-23 Suppresses Il-10 in Inflammatory Bowel Disease

Th17,Th17 Cytokines and Inflammatory Bowel Disease

Immune Regulation of Interleukin-23 on Peripheral Blood Natural Killer Cell in Patients with Inflammatory Bowel Disease

Hypoxia Inducible Factor-1Α-induced Interleukin-33 Expression in Intestinal Epithelia Contributes to Mucosal Homeostasis in Inflammatory Bowel Disease

Role of Interleukin-22 in Inflammatory Bowel Disease.

Research Progress of Th17 Cells and IL-23 in Inflammatory Bowel Disease

Role of the IL23/IL17 Pathway in Crohn's Disease

IL-23 plays a key role in Helicobacter hepaticus–induced T cell–dependent colitis

The role of Th17 cells in inflammatory bowel disease and the research progress

The Involvement of TH17 Cells in the Pathogenesis of IBD